Success Metrics

Clinical Success Rate
96.7%

Based on 29 completed trials

Completion Rate
97%(29/30)
Active Trials
0(0%)
Results Posted
24%(7 trials)
Terminated
1(3%)

Phase Distribution

Ph phase_4
21
68%
Ph phase_3
10
32%

Phase Distribution

0

Early Stage

0

Mid Stage

31

Late Stage

Phase Distribution31 total trials
Phase 3Large-scale testing
10(32.3%)
Phase 4Post-market surveillance
21(67.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

96.7%

29 of 30 finished

Non-Completion Rate

3.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

31

all time

Status Distribution
Completed(29)
Terminated(1)
Other(1)

Detailed Status

Completed29
unknown1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
31
Active
0
Success Rate
96.7%
Most Advanced
Phase 4

Trials by Phase

Phase 310 (32.3%)
Phase 421 (67.7%)

Trials by Status

unknown13%
completed2994%
terminated13%

Recent Activity

Clinical Trials (31)

Showing 20 of 31 trialsScroll for more
NCT05872568Phase 4

Efficacy and Safety of Enteric-Coated Mycophenolate Sodium (EC-MPS) in de Novo Kidney Transplant Recipients

Unknown
NCT00149968Phase 4

Measurement of Patient Reported Gastrointestinal (GI) and Health-related Quality of Life (HRQL) Outcomes in Renal Transplant Recipients (MyLife)

Completed
NCT00150007Phase 4

Measurement of Patient Reported Outcomes in Renal Transplant Patients With and Without Gastrointestinal (GI) Symptoms (PROGIS)

Completed
NCT00529269Phase 4

Measurement of Patient Reported Outcomes in Korean Renal Transplant Patients With and Without Gastrointestinal (GI) Symptoms

Completed
NCT00239005Phase 4

Enteric-Coated Mycophenolate Sodium on Quality of Life in Patients With Gastrointestinal Symptoms Related to Mycophenolate Mofetil Therapy After Kidney Transplantation

Completed
NCT00537862Phase 4

Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in a Cyclosporine Microemulsion Based Regimen in de Novo Living Donor Kidney Transplant Recipients

Completed
NCT00154206Phase 4

Study of Enteric-coated Mycophenolate Sodium (EC-MPS) With Cyclosporine Microemulsion and Steroids in Pediatric de Novo Renal Transplant Patients

Completed
NCT00240955Phase 4

Extension Study of Enteric-coated Mycophenolate Sodium With Short-term or no Steroid Use Compared With Enteric-coated Mycophenolate Sodium With Standard Steroid Therapy in de Novo Kidney Recipients

Completed
NCT00154245Phase 4

A One-year, Open Label Study to Investigate the Safety and the Effect of Enteric-coated Mycophenolate Sodium (EC-MPS) in Combination With Cyclosporine Microemulsion in de Novo Kidney Transplant Recipients.

Completed
NCT00239083Phase 4

Efficacy and Safety of Enteric-Coated Mycophenolate Sodium (EC-MPS) in Renal Transplant Patients

Completed
NCT00238953Phase 4

Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in de Novo Kidney Transplant Recipients

Completed
NCT00400647Phase 4

Gastrointestinal and Health-related Quality of Life in Kidney Transplant Patients Treated With Mycophenolate Mofetil

Completed
NCT00149942Phase 4

Conversion Trial From Mycophenolate Mofetil (MMF) to Enteric-coated Mycophenolate Sodium (EC-MPS) in Stable Transplanted Patients Suffering From Gastrointestinal (GI) Adverse Events While on Mycophenolate Mofetil Therapy (MMF) Therapy

Completed
NCT00154232Phase 4

Study to Evaluate the Combination of Enteric-coated Mycophenolate Sodium (EC-MPS), Basiliximab, and C2-monitored Cyclosporine in de Novo Renal Transplant Recipients at Potential High Risk of Delayed Graft Function (DGF)

Completed
NCT00238979Phase 4

A Study to Investigate the Tolerability and Safety of Converting Stable Renal Transplant Recipients Who Receive Tacrolimus With or Without Corticosteroids From Mycophenolate Mofetil (MMF) to Enteric-coated Mycophenolate Sodium (EC-MPS)

Completed
NCT00239044Phase 3

An Open Label Study to Evaluate the Tolerability and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in Combination With Cyclosporine Microemulsion (CsA-ME) in Maintenance Renal Transplant Recipients

Completed
NCT00238992Phase 3

Study of Enteric-coated Mycophenolate Sodium (EC-MPS) With Steroid Withdrawal vs EC-MPS With Standard Steroid Regimen in de Novo Renal Transplant Recipients.

Completed
NCT00284921Phase 3

MYPROMS-ES02: Safety and Efficacy of Basiliximab, Cyclosporine Microemulsion and Enteric-coated Mycophenolate Sodium (EC-MPS) Versus EC-MPS and Steroid Therapy in Kidney Transplant Recipients Who Are Hepatitis C Positive

Terminated
NCT00400400Phase 4

Enteric-coated Mycophenolate Sodium (EC-MPS) and Mycophenolate Mofetil (MMF) in Renal Transplant Patients With Gastrointestinal (GI) Intolerance

Completed
NCT00267150Phase 3

Gastrointestinal and Health-related Quality of Life Outcomes in Patients With Simultaneous Pancreas-Kidney Transplants

Completed

Drug Details

Intervention Type
DRUG
Total Trials
31